Display options
Cite
Castilow EM, Varga SM. Overcoming T cell-mediated immunopathology to achieve safe RSV vaccination. Future Virol. 2008;3(5):445-454doi: 10.2217/17460794.3.5.445.
Castilow, E. M., & Varga, S. M. (2008). Overcoming T cell-mediated immunopathology to achieve safe RSV vaccination. Future virology, 3(5), 445-454. https://doi.org/10.2217/17460794.3.5.445
Castilow, Elaine M, and Varga, Steven M. "Overcoming T cell-mediated immunopathology to achieve safe RSV vaccination." Future virology vol. 3,5 (2008): 445-454. doi: https://doi.org/10.2217/17460794.3.5.445
Castilow EM, Varga SM. Overcoming T cell-mediated immunopathology to achieve safe RSV vaccination. Future Virol. 2008;3(5):445-454. doi: 10.2217/17460794.3.5.445. PMID: 19057653; PMCID: PMC2593094.
Copy Download .nbib Format: NLM
Share it on

Future Virol. 2008;3(5):445-454. doi: 10.2217/17460794.3.5.445.

Overcoming T cell-mediated immunopathology to achieve safe RSV vaccination.

Future virology

Elaine M Castilow, Steven M Varga

Affiliations

  1. Interdisciplinary Graduate Program in Immunology, 51 Newton Road, 3-532 Bowen Science Building, University of Iowa, Iowa City, IA 52242.

PMID: 19057653 PMCID: PMC2593094 DOI: 10.2217/17460794.3.5.445

Abstract

Respiratory syncytial virus (RSV) is the leading cause of lower respiratory tract disease in young children. Premature infants, immunocompromised individuals, and the elderly exhibit an increased risk for the development of severe disease after RSV infection. Currently, there is not a safe and effective RSV vaccine available, in part due to our incomplete understanding of how severe immunopathology was induced following RSV infection of children previously immunized with a formalin-inactivated RSV vaccine. Much of our current understanding of RSV vaccine-enhanced disease can be attributed to the establishment of multiple mouse models of RSV vaccination. Studies analyzing the RSV-specific immune response in mice have clearly demonstrated that both CD4 and CD8 memory T cells contribute to RSV-induced immunopathology. In this review we will focus our discussion on data generated from the mouse models of RSV immunization that have advanced our understanding of how virus-specific T cells mediate immunopathology and RSV vaccine-enhanced disease.

References

  1. J Virol. 1996 May;70(5):2852-60 - PubMed
  2. Eur J Immunol. 2002 Aug;32(8):2117-23 - PubMed
  3. J Virol. 2005 Feb;79(4):2050-7 - PubMed
  4. J Am Geriatr Soc. 1990 Jun;38(6):659-62 - PubMed
  5. J Gen Virol. 1988 Feb;69 ( Pt 2):305-12 - PubMed
  6. N Engl J Med. 1992 Aug 13;327(7):453-7 - PubMed
  7. Pediatr Infect Dis J. 2007 Aug;26(8):733-9 - PubMed
  8. Dev Biol Stand. 1998;92:179-85 - PubMed
  9. Am J Epidemiol. 1969 Apr;89(4):449-63 - PubMed
  10. J Virol. 2007 Jul;81(13):6879-89 - PubMed
  11. Vaccine. 2007 Jun 15;25(25):4818-27 - PubMed
  12. J Clin Invest. 1994 Nov;94(5):1953-8 - PubMed
  13. J Immunol. 2000 Dec 1;165(11):6487-95 - PubMed
  14. Vaccine. 1998 Jul;16(11-12):1225-36 - PubMed
  15. J Immunol. 2007 Oct 15;179(8):5415-24 - PubMed
  16. J Virol. 1990 Sep;64(9):4232-41 - PubMed
  17. J Exp Med. 1998 Jun 1;187(11):1921-6 - PubMed
  18. Immunity. 2001 Oct;15(4):637-46 - PubMed
  19. Clin Microbiol Rev. 1996 Jul;9(3):293-300 - PubMed
  20. N Engl J Med. 1962 Jul 12;267:68-72 - PubMed
  21. J Immunol. 1967 Jun;98(6):1115-22 - PubMed
  22. J Virol. 2008 Mar;82(5):2196-207 - PubMed
  23. J Immunol. 1998 Nov 1;161(9):5027-38 - PubMed
  24. JAMA. 1994 May 4;271(17):1328-34 - PubMed
  25. Acta Paediatr. 2006 Apr;95(4):404-6 - PubMed
  26. Pediatrics. 1991 Sep;88(3):527-32 - PubMed
  27. Intern Med. 1997 Mar;36(3):179-85 - PubMed
  28. J Immunol. 2008 Feb 15;180(4):2376-84 - PubMed
  29. J Immunol. 1997 Jul 1;159(1):328-34 - PubMed
  30. J Virol. 1999 Oct;73(10):8485-95 - PubMed
  31. J Virol. 1999 Aug;73(8):6590-7 - PubMed
  32. J Immunol. 1998 Dec 1;161(11):6215-22 - PubMed
  33. J Exp Med. 1988 Jan 1;167(1):43-56 - PubMed
  34. J Virol. 2004 Aug;78(16):8753-60 - PubMed
  35. J Infect Dis. 1991 Apr;163(4):693-8 - PubMed
  36. J Virol. 2006 May;80(9):4521-7 - PubMed
  37. Int Immunol. 1992 Apr;4(4):493-500 - PubMed
  38. Virology. 2005 Jul 5;337(2):335-43 - PubMed
  39. J Exp Med. 1998 Nov 16;188(10):1967-72 - PubMed
  40. J Immunol. 2003 Feb 15;170(4):2037-45 - PubMed
  41. Can J Comp Med. 1980 Oct;44(4):390-5 - PubMed
  42. J Med Virol. 1990 Feb;30(2):117-27 - PubMed
  43. J Med Virol. 2003 Jun;70(2):301-8 - PubMed
  44. Eur J Immunol. 1997 Dec;27(12):3341-9 - PubMed
  45. J Exp Med. 2001 Apr 2;193(7):785-92 - PubMed
  46. J Exp Med. 1997 Aug 4;186(3):421-32 - PubMed
  47. J Virol. 1990 Apr;64(4):1683-9 - PubMed
  48. N Engl J Med. 1982 Aug 12;307(7):397-400 - PubMed
  49. J Immunol. 1986 Dec 15;137(12):3973-7 - PubMed
  50. Nat Med. 2006 Aug;12(8):905-7 - PubMed
  51. J Exp Med. 1988 May 1;167(5):1737-42 - PubMed
  52. Paediatr Respir Rev. 2004;5 Suppl A:S119-26 - PubMed
  53. J Virol. 2004 Jun;78(11):6024-32 - PubMed
  54. J Immunol. 2007 Aug 1;179(3):1648-58 - PubMed
  55. Am J Epidemiol. 1969 Apr;89(4):422-34 - PubMed
  56. J Gen Virol. 1987 Aug;68 ( Pt 8):2177-82 - PubMed
  57. J Immunol. 2005 Oct 1;175(7):4735-44 - PubMed
  58. N Engl J Med. 2005 Apr 28;352(17):1749-59 - PubMed
  59. J Virol. 1997 Jan;71(1):678-85 - PubMed
  60. Lancet. 1999 Sep 4;354(9181):847-52 - PubMed
  61. Pediatr Cardiol. 2000 Sep-Oct;21(5):433-8 - PubMed
  62. Vaccine. 2004 Mar 29;22(11-12):1465-74 - PubMed
  63. Am J Epidemiol. 1969 Apr;89(4):405-21 - PubMed
  64. Eur J Immunol. 2001 Sep;31(9):2566-73 - PubMed
  65. J Virol. 1998 Apr;72(4):2871-80 - PubMed
  66. Am J Epidemiol. 1969 Apr;89(4):435-48 - PubMed
  67. N Engl J Med. 1986 Jul 10;315(2):77-81 - PubMed
  68. Blood. 2007 Sep 1;110(5):1578-86 - PubMed

Publication Types

Grant support